Innospec (NASDAQ: IOSP) is one of 53 publicly-traded companies in the “Specialty Chemicals” industry, but how does it weigh in compared to its competitors? We will compare Innospec to similar companies based on the strength of its earnings, risk, valuation, dividends, profitability, institutional ownership and analyst recommendations.

Valuation and Earnings

This table compares Innospec and its competitors gross revenue, earnings per share (EPS) and valuation.

Gross Revenue NetIncome Price/Earnings Ratio
Innospec $883.40 million $81.30 million 20.13
Innospec Competitors $2.04 billion $125.71 million 266.02

Innospec’s competitors have higher revenue and earnings than Innospec. Innospec is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Innospec and its competitors, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Innospec 0 0 1 0 3.00
Innospec Competitors 166 1033 1288 24 2.47

Innospec currently has a consensus price target of $65.00, indicating a potential upside of 3.17%. As a group, “Specialty Chemicals” companies have a potential downside of 10.28%. Given Innospec’s stronger consensus rating and higher probable upside, equities analysts clearly believe Innospec is more favorable than its competitors.

Dividends

Innospec pays an annual dividend of $0.76 per share and has a dividend yield of 1.2%. Innospec pays out 24.3% of its earnings in the form of a dividend. As a group, “Specialty Chemicals” companies pay a dividend yield of 1.3% and pay out 27.0% of their earnings in the form of a dividend.

Risk and Volatility

Innospec has a beta of 1.16, indicating that its stock price is 16% more volatile than the S&P 500. Comparatively, Innospec’s competitors have a beta of 1.39, indicating that their average stock price is 39% more volatile than the S&P 500.

Institutional and Insider Ownership

89.1% of Innospec shares are held by institutional investors. Comparatively, 69.1% of shares of all “Specialty Chemicals” companies are held by institutional investors. 2.0% of Innospec shares are held by insiders. Comparatively, 7.1% of shares of all “Specialty Chemicals” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Innospec and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Innospec 7.22% 14.77% 8.39%
Innospec Competitors -2.60% 8.94% 3.92%

Summary

Innospec beats its competitors on 8 of the 15 factors compared.

Innospec Company Profile

Innospec Inc. is a specialty chemicals company engaged in developing, manufacturing, blending, marketing and supplying of specialty chemicals for use as fuel additives and ingredients for personal care, home care, agrochemical, mining and other applications and oilfield chemicals. The Company operates through four business segments: Fuel Specialties, Performance Chemicals, Oilfield Services and Octane Additives. Its Fuel Specialties develops, manufactures, blends, markets and supplies various specialty chemical products that are used as additives for a range of fuels. Its Performance Chemicals provides technology-based solutions. Its Oilfield Services business supplies drilling, completion and production chemicals. Its Octane Additives business manufactures a fuel additive for use in automotive gasoline and provides services in respect of environmental remediation. Its customers include oil and gas exploration and production companies, fuel users, and oil refiners among others.

Receive News & Ratings for Innospec Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innospec Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.